Mesothelioma is a rare and aggressive form of cancer that develops in the mesothelial tissue lining the lungs, abdomen, or heart. Mesothelioma is caused by exposure to asbestos, and though long-term exposure leads to a greater risk of developing the disease, short-term and one-time exposures to asbestos are also known to cause this cancer. Asbestos use in the United States has dropped dramatically in recent decades, and yet a steady number of people continue to be diagnosed with mesothelioma each year due to the fact that it can take anywhere from 20 to 50 years after asbestos exposure for symptoms to appear. Approximately 3,000 people are diagnosed with mesothelioma each year in the United States, with the disease occurring more often in men than in women.
Doctors have traditionally used a few basic methods to test for mesothelioma. Most patients initially undergo a basic chest x-ray to check for abnormalities, with more detailed imaging scans (such as a PET, CT, or MRI scan) being recommended if any growth is detected. If cancer is suspected, the doctor will usually take a tissue sample, called a biopsy, to definitely confirm the presence of mesothelioma cells. Blood tests have been available as well, but the tests could not confirm the presence of mesothelioma to the same degree of accuracy as imaging scans and biopsies. Due to the limitations of these tests, it has been estimated that up to 10 percent of mesothelioma cases are being misdiagnosed in the United States each year.
However, researchers at the University of Hawaii Cancer Center have recently identified another tool for diagnosing pleural mesothelioma. Dr. Michele Carbone and his research team have discovered that a tumor-suppressing protein called BAP1 can help oncologists accurately differentiate mesothelioma from other lung cancers, insofar as people lacking the BAP1 protein are more likely to develop mesothelioma than the general population. Specifically, the study found that all 45 non-small lung cancer samples tested positive for normal BAP1 expression, whereas only half of the 35 pleural mesothelioma samples tested positive for BAP1.
Based on these results, researchers believe that the diagnostic accuracy of mesothelioma tests would be better if BAP1 were included in the recommended panels. Given that the inability to diagnose mesothelioma in the earliest stages is a major reason why the life expectancy of a mesothelioma patient is so short (6-18 months), better early detection accuracy could greatly expand a patient’s treatment options.
If you would like more information about these cases, you can contact Grant Cofer, a lawyer in our firm’s Toxic Torts Section. He can be reached at 800-898-2034 or by email at Grant.Cofer@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.